Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts

BACKGROUND: Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers. The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose and treat at early stages. Currently approved second-line treatments following s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Macura, Sherrill L, Steinbacher, Jeremy L, MacPherson, Maximilian B, Lathrop, Melissa J, Sayan, Mutlay, Hillegass, Jedd M, Beuschel, Stacie L, Perkins, Timothy N, Spiess, Page C, van der Vliet, Albert, Butnor, Kelly J, Shukla, Arti, Wadsworth, Marilyn, Landry, Christopher C, Mossman, Brooke T
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3846908/
https://ncbi.nlm.nih.gov/pubmed/24024776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-400
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars